Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Ibrutinib is a targeted therapy used for various cancers and chronic graft-versus-host disease.
• Dermatologic adverse events associated with ibrutinib have not been systematically characterized.
• Effective management of these toxicities is essential for patient adherence and treatment success.

Purpose of the Study:

• To systematically describe the incidence and severity of dermatologic adverse events linked to ibrutinib.
• To provide evidence-based management recommendations for ibrutinib-associated skin toxicities.

Main Methods:

• A systematic literature search was conducted for clinical trials and cohorts involving ibrutinib monotherapy.
• Studies published up to June 2020 were included, focusing on cancer or chronic graft-versus-host disease.
• Data from 32 studies encompassing 2258 patients were analyzed.

Main Results:

• Common all-grade toxicities included cutaneous bleeds (24.8%), edema (15.9%), rash (10.8%), xerosis (9.2%), and nail changes (17.8%).
• High-grade toxicities were less frequent, with mucocutaneous infection (1.3%) and rash (0.1%) being notable.
• Specific incidences for mucocutaneous infections, mucositis, pruritus, and hair changes were also reported.

Conclusions:

• Clinicians must be aware of the spectrum of ibrutinib-induced dermatologic toxicities.
• Prompt recognition and management of these adverse events can prevent treatment discontinuation.
• Familiarity with these toxicities will improve patient outcomes and adherence to ibrutinib therapy.